Intravenous immunoglobulin therapy for SLE

Ziv Rozman*, Gisele Zandman-Goddard

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Intravenous immunoglobulin (IVIg) is an adjunct therapy for refractory disease or for patients that refuse conventional steroid and immunosuppressive treatment. IVIg has a good beneficial and safety profile ; a steroid-sparing effect and long-term high-dose IVIg therapy remains beneficial and safe. IVIg is contraindicated in patients with IgA deficiency, renal failure, or increased risk factors for thromboembolic disease.

Original languageEnglish
Title of host publicationImmunotherapeutic Agents for SLE
PublisherFuture Medicine Ltd.
Number of pages8
ISBN (Electronic)9781780840529
ISBN (Print)9781780841267
StatePublished - 1 Feb 2012


Dive into the research topics of 'Intravenous immunoglobulin therapy for SLE'. Together they form a unique fingerprint.

Cite this